



September 27, 2013

AnGes MG, Inc.

Notice Concerning Acquisition and Cancellation of the 24th Series of Stock Acquisition Rights (Private Placement) (with Option to Revise Exercise Price)

With regard to AnGes MG Inc. 24th series of stock acquisition rights (private placement) (“the stock acquisition rights”) issued on May 20, 2013, the Company at today’s board of directors meeting resolved to acquire and cancel all the remaining stock acquisition rights as follows. AnGes MG received notice from the stock acquisition rights holder Merrill Lynch Japan Securities Co., Ltd. (“the stock acquisition rights holder”) that the company will request for the acquisition of all the remaining stock acquisition rights based on the provision of private placement agreement with a commitment clause (“the private placement agreement”) related to the stock acquisition rights between AnGes MG and the stock acquisition rights holder. Therefore, AnGes MG will acquire and cancel all the stock acquisition rights based on the provisions of the private placement agreement, acquisition clause for the stock acquisition rights and Companies Act.

1. Description, the number and acquisition price of the stock acquisition rights to be acquired and cancelled

(1) Name of stock acquisition rights	AnGes MG Inc. 24 th Series of Stock Acquisition Rights (Private Placement)
(2) Number of stock acquisition rights	12,700 rights
(3) Acquisition price	Total of 17,081,500 yen (1,345 yen per stock acquisition right)

2. Acquisition and cancellation dates of the stock acquisition rights

(1) Acquisition date	October 15, 2013
(2) Cancellation date	October 15, 2013

In the private placement agreement, AnGes MG may designate a period during which the stock acquisition rights holder cannot exercise all or part of the stock acquisition rights (“suspension designation”) and the Company will suspend designation of all the remaining stock acquisition rights from September 30, 2013 to October 15, 2013.

3. Future outlook

The purpose of procuring funds through the stock acquisition rights is to apply to the fees for the global Phase 3 Trial of “Collatogene®” for peripheral cardiovascular disease, which are expected to be incurred by 2018 and AnGes MG planned to procure about 5.0 billion yen. To this date, the Company has procured a total of 1,985,937,500 yen by exercising the stock acquisition rights. AnGes MG will quickly consider and plan other ways to procure the shortfall in development funds which the Company expected to procure by exercising the remaining stock acquisition rights. This matter will have no effect on the start of the global Phase 3 Trial of “Collatogene®.”

【Reference】 Summary of AnGes MG 24th series of stock acquisition rights (private placement)

Date of allocation	May 20, 2013
Allottee	Merrill Lynch Japan Securities Co., Ltd.
Total number of stock acquisition rights	20,000 rights
Total amount of payment	Total of 26,900,000 yen (1,345 yen per stock acquisition right)
Number of stock acquisition rights exercised to this date	7,300 rights

For details, please see May 1, 2013 press release titled “Notice Concerning Issue of the 24th Series of Stock Acquisition Rights (Private Placement) (with Option to Revise Exercise Price) and Private Placement Agreement with Commitment Clause.”

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

AnGes MG, Inc. Corporate Communications TEL:+81-3-5730-2641, FAX:+81-3-5730-2635 http://www.anges-mg.com Email:info@anges-mg.com
--